NCT00535496View on ClinicalTrials.gov

Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)

PHASE3CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

February 29, 2008

Conditions
Neuromuscular Blockade
Interventions
DRUG

sugammadex

Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00535496 - Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698) | Biotech Hunter | Biotech Hunter